Document:

License Agreement dated May 3, 2004

 EXHIBIT 10.9 
 CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR SUCH PORTIONS. ASTERISKS DENOTE OMISSIONS. 
 LICENSE AGREEMENT 
 THIS AGREEMENT,
effective as of May 3, 2004 (“EFFECTIVE DATE”) between THE GENERAL HOSPITAL CORPORATION, a not-for-profit corporation doing business as Massachusetts General Hospital, having a place of business at Fruit Street, Boston, Massachusetts
02114 (“GENERAL”) and Dara Pharmaceuticals, Inc., a corporation having offices at 1234 Airport Road, Suite 105, Destin, Florida 32541 (“COMPANY”). 
 WHEREAS, under research programs funded by GENERAL and the U.S. Government, GENERAL through research conducted by Dr. David Borsook and Dr. Jeffrey Clark has developed an invention pertaining to methods for
decreasing or preventing pain (MGH Case nos. 1229 and 1725); and 
 WHEREAS, GENERAL represents to the best of its knowledge and belief that
it is the owner of all rights, title and interest in the patents and patent applications relating to the invention described above and has the right and ability to grant the license hereinafter described; and 
 WHEREAS, as a center for research and education, GENERAL is interested in licensing PATENT RIGHTS and thus benefiting the public and GENERAL by
facilitating the dissemination of the results of its research in the form of useful products, but is without capacity to commercially develop, manufacture, and distribute any such product; and 
 WHEREAS, COMPANY desires to support the development of such products and, in collaboration with GENERAL, to develop approaches for the commercialization
of such products throughout the world. 
 NOW THEREFORE, in consideration of the premises and of the faithful performance of the covenants
herein contained, the parties hereto agree as follows: 
 1. DEFINITIONS 
 1.1 The term “ACCOUNTING PERIOD” shall mean each six-month period ending June 30 and December 31. 
 1.2 The term “AFFILIATE” shall mean any corporation or other legal entity other than COMPANY in whatever country organized, controlling,
controlled by or under common control with COMPANY. The term “control” means possession, direct or indirect, of the powers to direct or cause the direction of the management and policies of an entity, whether through the ownership of
voting securities, by contract or otherwise. The term “AFFILIATE” with respect to GENERAL shall mean any company controlling, controlled by, or under common control, directly or indirectly, with GENERAL. 
 1.3 The term “LIQUIDITY EVENT” shall mean the sale or transfer of all or substantially all of the assets or equity securities of COMPANY (by
sale, merger, consolidation or otherwise). 

 1.4 The term “NET SUBLICENSE INCOME” shall mean any and all royalty and non-royalty income,
including without limitation license fees and milestone payments, received from its SUBLICENSEES in consideration for the sublicensing of any right or license under the PATENT RIGHTS granted to COMPANY hereunder, less any amounts payable to KIRIN
under the KIRIN AGREEMENT and any amounts payable to third parties with respect to licenses of patents or technology necessary to practice the invention claimed in the PATENT RIGHTS. 
 1.5 The term “PARENT” shall mean Dara BioSciences, Inc and its subsidiaries, directors and officers. 
 1.6 The term “PATENT RIGHTS” shall mean the U.S. Patent No. 5,905,609 and the PCT. Patent Application Serial No. US0129371, publication
number WO02-24146 or the equivalent of such application or the application resulting in U.S. Patent No. 5,905,609, including any division, continuation or any foreign patent application or Letters Patent or the equivalent thereof issuing
thereon or any reissue, reexamination, supplementary protection certificate or extension thereof. PATENT RIGHTS shall also include those claims in any continuation-in-part of the aforementioned patent applications which claim an invention described
or claimed in said patent applications. PATENT RIGHTS as of the EFFECTIVE DATE are listed in Appendix A. 
 1.7 The term “PRODUCT”
shall mean any article, device, composition, method or service, the manufacture, use, or sale of which 
 (a) absent the licenses granted
herein, would infringe a VALID CLAIM of any PATENT RIGHT, or 
 (b) does not infringe a VALID CLAIM of any PATENT RIGHT licensed to COMPANY
hereunder but the discovery, development, manufacture or use of which infringes a VALID CLAIM of any PATENT RIGHT, or 
 (c) does not
infringe a VALID CLAIM of any PATENT RIGHT licensed to COMPANY hereunder but the discovery, development or manufacture uses or incorporates TECHNOLOGICAL INFORMATION. 
 1.8 The term “SUBLICENSEE” shall mean any non-AFFILIATE third party licensed by COMPANY or by an AFFILIATE to make, have made, use or sell any PRODUCT. As used in this Agreement, “SUBLICENSEE”
shall include any third party to whom COMPANY has granted, directly or indirectly, the right to distribute a PRODUCT, provided that such third party has the responsibility in whole or in part for marketing and/or promotion of the PRODUCT within the
territory for which such distribution rights are granted. 
 1.9 The term “TECHNOLOGICAL INFORMATION” shall mean any research data,
designs, formulas, process information, clinical data and other information owned or controlled by GENERAL pertaining to any invention claimed in PATENT RIGHTS or any improvement to any such invention which is known, as of the EFFECTIVE DATE, to
Dr. Borsook or Dr. Clark. 
  

 2 

 1.10 The term “VALID CLAIM” shall mean any claim of any PATENT RIGHT that has not been
(i) finally rejected or (ii) declared invalid by a patent office or court of competent jurisdiction in any unappealed and unappealable decision. 
 2. LICENSE 
 2.1 GENERAL hereby grants COMPANY, to the extent not prohibited by the United States
Government or by contractual obligations to any other sponsor listed on Appendix B of research at GENERAL: 
  

	 	(a)	an exclusive, worldwide, license under GENERAL’S rights in PATENT RIGHTS to develop, have developed, make, have made, use, have used, sell, have sold, offer for sale, import
and have imported PRODUCTS; 

  

	 	(b)	a non-exclusive, worldwide, license under GENERAL’S rights in TECHNOLOGICAL INFORMATION; 

  

	 	(c)	the right to sublicense PATENT RIGHTS exclusively licensed to COMPANY. 

 The above licenses to sell PRODUCTS include the right to grant to the purchaser of PRODUCTS from COMPANY, its AFFILIATES and SUBLICENSEES the right to use such purchased PRODUCTS in a method coming within the scope of
PATENT RIGHTS. 
 2.2 In all sublicenses granted by COMPANY hereunder, COMPANY agrees that: 
 (a) the terms and conditions of each sublicense shall be consistent with the terms and conditions of this Agreement; and 
 (b) each sublicense shall provide that the obligations to GENERAL of Sections 7 and 9.4 shall be binding on the SUBLICENSEE and be enforceable both by
GENERAL and COMPANY; and 
 (c) COMPANY shall furnish to GENERAL a true and complete copy of each sublicense agreement and each amendment
thereto, within thirty (30) days after the sublicense or amendment has been executed; provided, that COMPANY may redact trade secret or confidential information from such copy; and 
 (d) no sublicense shall relieve COMPANY of any of its obligations hereunder, and COMPANY shall be responsible for the acts or omissions of its
SUBLICENSEES and for compliance by them with their obligations, and COMPANY shall take all steps necessary to enforce that compliance to the extent required to allow COMPANY to fully comply with all of its obligations under this Agreement.

 2.3 The granting of any license hereunder is subject to GENERAL’S and GENERAL’S AFFILIATES’ right to make and to use the
subject matter described and claimed in PATENT RIGHTS for research, clinical and educational purposes but for no other purpose, provided, however, that such use and the licensing of the results of such use shall not conflict 

  

 3 

 
with the provisions of this Agreement, and if federal funding supported the PATENT RIGHTS, COMPANY’S license will be subject to the rights, conditions
and limitations imposed by U.S. law including without limitation the royalty-free non-exclusive license granted to the U.S. government (see 35 U.S.C. § 202 et seq. and regulations pertaining thereto). 
 2.4 Within thirty (30) days of EFFECTIVE DATE, upon request by COMPANY, GENERAL through Drs. Borsook and Clark shall disclose to COMPANY
TECHNOLOGICAL INFORMATION which COMPANY will be entitled to use to the extent such use does not infringe any patent owned by GENERAL not licensed to COMPANY hereunder. GENERAL will use reasonable efforts to notify COMPANY of any inventions which
constitute improvements to the inventions claimed in PATENT RIGHTS. 
 2.5 Nothing herein shall be construed to grant COMPANY a license
express or implied under any patent owned solely or jointly by GENERAL other than the PATENT RIGHTS expressly licensed hereunder. 
 3.
OBLIGATIONS OF THE PARTIES 
 3.1 COMPANY shall itself, or through its AFFILIATES, use commercially reasonable efforts to achieve the
following objectives within the time period designated below: 
 (a) within six (6) months after the EFFECTIVE DATE, provide General with
a plan and protocol and funding to support a proof of principle clinical trial subject to Section 3.2 hereof; and 
 (b) within six
(6) months after the EFFECTIVE DATE, receipt by COMPANY of a fully executed agreement(s) between COMPANY and Kirin Brewery Company Limited (“KIRIN”) providing a license grant under KIRIN’S rights in U.S. Patents
No. 5,631,238 and No. 5,461,036 to COMPANY (the “KIRIN AGREEMENT”), and 
 (c) with six (6) months after receipt by
COMPANY, from Kirin, of a sufficient quantity of bulk active drug substance, that is deemed by COMPANY to be suitable for human clinical trials, to manufacture drug product for the proof of principle clinical trial subject to Section 3.2
hereof; and 
 (d) within eight (8) months after the earlier of (i) the EFFECTIVE DATE or (ii) receipt by COMPANY of the KIRIN
AGREEMENT, raise an aggregate of financing of $2 million dollars or more; and 
 (e) within three (3) months after the completion
(including data analysis and a final report in customary form) of the clinical trial to be conducted pursuant to Section 3.1(a) or 24 months after the EFFECTIVE DATE, whichever is the earlier, meet with GENERAL to report on and discuss
COMPANY’S strategy for further technology development, provided, however, that GENERAL shall not unreasonably withhold its consent to any revision in such time periods whenever requested in writing by COMPANY and supported by evidence of
technical difficulties or delays in clinical studies that COMPANY could not have reasonably avoided. Failure to achieve one or more of the above objectives within the above stated time periods or 

  

 4 

 
within any extension granted by GENERAL shall result in GENERAL having the right to terminate this Agreement on sixty (60) days’ notice (unless
such failure is cured during a sixty (60) day period) or to convert any exclusive license granted hereunder to a non-exclusive license on sixty (60) days’ notice (unless such failure is cured during a sixty (60) day period).

 3.2. If GENERAL is selected as a clinical site, GENERAL shall use reasonable efforts, no less than the efforts used to conduct similar
clinical research programs at GENERAL, to complete patient enrollment and conduct the proof of principle clinical trial of Section 3.1(a) (including data analysis and delivery of a final report in customary form), according to the timelines
agreed to by the parties hereto and pursuant to a clinical trial agreement between the parties (the “CLINICAL TRIAL AGREEMENT”). 
 3.3. Company shall permit an observer appointed by GENERAL and satisfactory to COMPANY to attend all meetings of the Board of Directors of COMPANY. COMPANY shall consult with GENERAL with respect to commercialization of PRODUCTS, including,
without limitation, selection and negotiations with third parties for development and commercialization of PRODUCTS; provided, that COMPANY shall have the right to make all final decisions with respect to such matters. 
 4. FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHT 
 4.1 Within thirty (30) days after execution of this Agreement, COMPANY shall reimburse GENERAL for all reasonable out-of-pocket expenses incurred by GENERAL for the preparation, filing, prosecution and
maintenance of PATENT RIGHTS (“Costs”). COMPANY shall also reimburse GENERAL for all such expenses it incurs prior to COMPANY’S assumption of these Costs. As of April 12, 2004, said costs total [***]. 
 4.2 As soon as reasonably possible after execution of this Agreement, COMPANY shall assume primary responsibility for the filing, prosecution and
maintenance of any and all patents and patent applications included in PATENT RIGHTS, using patent counsel of COMPANY’s choice and reasonably acceptable to GENERAL, and COMPANY shall be responsible for all Costs relating thereto. Counsel will
directly notify GENERAL and COMPANY and provide them copies of any official communications from the United States and foreign patent offices relating to said prosecution. Counsel shall also provide GENERAL with advance copies of all relevant
communications to the various patent offices, so that GENERAL may be informed and apprised of the continuing prosecution of patent applications in PATENT RIGHTS. GENERAL shall have reasonable opportunities to participate in decision making on all
key decisions affecting filing, prosecution and maintenance of patents and patent applications in PATENT RIGHTS including, without limitation, the right to approve or disapprove the abandonment of any patent or claims thereof and COMPANY will use
reasonable efforts to incorporate GENERAL’s reasonable suggestions regarding said prosecution. COMPANY shall use all reasonable efforts to amend any patent application to include claims reasonably requested by GENERAL to protect PRODUCTS.

 4.3 GENERAL and COMPANY agree to cooperate fully in the preparation, filing, prosecution and maintenance of PATENT RIGHTS and of all
patents and patent applications licensed to COMPANY hereunder, executing all papers and instruments or requiring members of GENERAL to execute such papers and instruments so as to enable COMPANY to apply for, to prosecute and to maintain patent
applications and patents in GENERAL’s name in any country. 
  

 5 

 4.4 If COMPANY elects no longer to pay the expenses of a patent application or patent included within
PATENT RIGHTS, COMPANY shall notify GENERAL in writing not less than sixty (60) days prior to such action, such date being at least 30 (thirty) days prior to any pending action or expenditure, and shall thereby surrender its rights under such
patent or patent application. 
 4.5 In the event that COMPANY elects not to prosecute or maintain any of the patents or patent applications
relating to the PATENT RIGHTS or any portion thereof in any jurisdiction, then GENERAL shall have the right, at its own expense to prosecute or maintain the patents or patent applications relating to the PATENT RIGHTS or portion thereof in such
jurisdiction, but COMPANY shall have no further rights to such patents or patent applications or portion thereof. 
 4.6 GENERAL shall
engage, at COMPANY’s expense, independent patent counsel to review and evaluate patent prosecution and filing of patents and patent applications included in PATENT RIGHTS. GENERAL agrees that it will not incur costs in excess of $15,000 per
year without prior written notice to COMPANY. If GENERAL can demonstrate that it is not being adequately informed or apprised of the continuing prosecution of patents or patent applications in PATENT RIGHTS, or that it is not being provided with
reasonable opportunities to participate in decision making or that its interests are not being adequately protected, GENERAL shall assume primary responsibility for future prosecution and maintenance of patents and patent applications in PATENT
RIGHTS. 
 5. COMPENSATION 
 5.1 As consideration for the licenses granted hereunder, COMPANY shall pay to GENERAL a nonrefundable license fee in the amount of [***]. The license fee will be paid in the form of a Non-Negotiable Promissory Note
(the “NOTE”) in the original principal amount of [***] to be issued to GENERAL within thirty (30) days of the EFFECTIVE DATE. The amount of [***] of the NOTE shall become due upon demand of GENERAL made twenty-four (24) months
following the EFFECTIVE DATE (the “FIRST PAYMENT”) and shall for such twenty-four (24) month period be interest-free but shall thereafter bear interest pursuant to the terms of the NOTE. The remaining [***] (the “SECOND
PAYMENT”) shall be due upon demand of GENERAL made thirty-six (36) months following the EFFECTIVE DATE and shall for such thirty-six (36) month period be interest-free but shall thereafter bear interest pursuant to the terms of the
NOTE. COMPANY may prepay all or any portion of the NOTE at any time. COMPANY may choose to pay the NOTE in cash or by the issuance and delivery of shares of its common stock, where the number of shares due would be equal to [***], plus accrued
interest, if any, divided by the value of the stock at the time of conversion determined as set forth in the NOTE, provided however that COMPANY must pay the NOTE in cash if acceptance of equity by GENERAL would, under GENERAL’S policies then
in force, put GENERAL into an unacceptable conflict of interest situation and GENERAL advises COMPANY of such conflict 

  

 6 

 
situation in writing and provides COMPANY with a right to appeal such determination through appropriate channels at GENERAL. Except in the foregoing case
where payment of the NOTE must be made in cash because of a conflict of interest situation, should COMPANY choose to make either of or both of the FIRST PAYMENT and the SECOND PAYMENT to GENERAL in cash rather than in stock, COMPANY shall pay an
additional fee of [***] at the time of the final cash payment of the NOTE. For the avoidance of doubt, no interest shall accrue on such additional fee. In the event of a conflict between the terms of the NOTE and the terms of this License Agreement,
the terms of the NOTE shall govern. 
 5.2 Unless and until the NOTE has been paid or satisfied, (i) COMPANY shall pay GENERAL [***] of
NET SUBLICENSE INCOME (as defined below) received by the Company and (ii) in the event of a LIQUIDITY EVENT prior to the full payment or satisfaction of the NOTE, COMPANY shall pay to GENERAL an amount equal to [***] of the consideration
payable to COMPANY and/or its stockholders in respect of such LIQUIDITY EVENT, provided that (1) all payments made by Company to GENERAL under clause (ii) above shall be made in the same form as the consideration paid or payable to Company
and/or its stockholders in such LIQUIDITY EVENT and all forms of consideration other than cash delivered to GENERAL shall be valued at the same value as such consideration is valued for purposes of the LIQUIDITY EVENT and (2) all payments made
by the COMPANY in cash under the NOTE, including without limitation, the additional fee of [***] (if paid) shall be credited against any amounts due to GENERAL pursuant to clauses (i) and (ii) of this sentence. 
 5.3 If a LIQUIDITY EVENT occurs after the full payment or satisfaction of the Note and GENERAL is at the time of such LIQUIDITY EVENT a stockholder of
COMPANY, GENERAL shall be entitled to receive its pro rata share of the consideration payable to stockholders of COMPANY in connection with such LIQUIDITY EVENT based upon its holding of shares of COMPANY’S capital stock (on an as-converted
basis) at such time. 
 5.4 As promptly as practicable after COMPANY enters into the first sublicense agreement entered into by COMPANY with
a SUBLICENSEE after the full payment or satisfaction of the NOTE and provided GENERAL is at such time a stockholder of COMPANY, COMPANY shall provide written notice to GENERAL of such first sublicense agreement. Such notice from COMPANY shall
constitute a written offer by COMPANY to repurchase from GENERAL all, but not less than all, of the shares of Company’s Common Stock held by GENERAL in consideration for the COMPANY agreeing to pay to GENERAL the APPLICABLE PERCENTAGE (as
defined below) of NET SUBLICENSE INCOME received by COMPANY on or after the date of such first sublicense agreement under such first sublicense agreement and all other sublicense agreements entered into by COMPANY. For purposes of this
Section 5.4, “APPLICABLE PERCENTAGE” shall equal the percentage of the outstanding shares of COMPANY’s capital stock (on an as-converted basis) held by GENERAL on the date of such first sublicense agreement. If GENERAL wishes to
accept COMPANY’s offer and resell to COMPANY all of the shares of Company’s Common Stock held by GENERAL for the consideration set forth above, GENERAL shall so notify COMPANY within 60 days of the delivery of the notice from COMPANY to
GENERAL of the first sublicense agreement. If GENERAL fails to so notify COMPANY within such 60 day period, GENERAL will be deemed 

  

 7 

 
to have rejected COMPANY’s offer to purchase GENERAL’s shares of Common Stock, shall continue as a stockholder of COMPANY and shall not be entitled
to receive any portion of NET SUBLICENSE INCOME. GENERAL’s option to resell its shares of Common Stock to COMPANY shall occur on one occasion only following the entry by COMPANY into the first sublicense agreement entered into by COMPANY with a
SUBLICENSEE after the full payment or satisfaction of the NOTE and shall terminate if not timely exercised by GENERAL in accordance with this Section 5.4. 
 5.5 Payments due under this Agreement shall, if overdue, bear interest until payment at a per annum rate equal to two percent (2%) above the prime rate of Bank of America in effect on the due date, not to exceed
the maximum permitted by law. The payment of such interest shall not preclude GENERAL from exercising any other rights it may have as a consequence of the lateness of any payment. 
 5.6 After the EFFECTIVE DATE, (i) COMPANY will not issue and sell to PARENT any equity securities of COMPANY at a price lower than the then fair
market value as determined in good faith by the Board of Directors of COMPANY, and, if there are disinterested directors, by a majority of such disinterested directors and (ii) if GENERAL is at the time of such issuance and sale a stockholder
of COMPANY, GENERAL shall have the right and opportunity to purchase its pro rata share of any equity securities of COMPANY that proposes to issue and sell to PARENT based upon the respective holdings of PARENT and GENERAL of shares of
COMPANY’s capital stock (on an as-converted basis). 
 6. REPORTS AND PAYMENTS 
 6.1 The provisions of this Article 6 shall apply unless and until such time as COMPANY shall pay the NOTE by conversion to common stock. Thereafter, this
Article 6 shall have no force or effect. 
 6.2 COMPANY shall keep, and shall cause each of its AFFILIATES and SUBLICENSEES, if any, to keep
full and accurate books of accounts containing all particulars that may be necessary for the purpose of calculating all amounts payable to GENERAL. Such books of account shall be kept at their principal place of business and, with all necessary
supporting data shall, during all reasonable times for the three (3) years next following the end of the calendar year to which each shall pertain be open for audit in accordance with Section 6.3. 
 6.3 GENERAL shall have the right to have COMPANY’S books and records audited by an independent accountant of GENERAL’S choosing, reasonably
acceptable to COMPANY, to ascertain the accuracy of COMPANY’S reports. Such audits shall not occur more than once per year and be limited to the extent necessary to verify the amount payable hereunder. Such examination shall be at
GENERAL’S expense, except that if such examination shows an underreporting or underpayment in excess of five percent (5%) for any twelve (12) month period, the COMPANY shall pay the cost of such examination as well as any additional
sum that would have been payable to GENERAL had COMPANY reported correctly plus interest on said sum at the rate of one percent (1%) per month. GENERAL agrees to hold in strict confidence all information concerning payments and reports and all
information learned in the course of any audit, except to the extent necessary for GENERAL to enforce its rights under this Agreement or if disclosure is required by law. 
  

 8 

 6.3 In each year the amount due shall be calculated semiannually as of the end of each ACCOUNTING PERIOD
and shall be paid semiannually within the sixty (60) days next following such date, every such payment to be supported by the accounting prescribed in paragraph 6.4 and to be made in United States currency. Whenever conversion from any foreign
currency shall be required, such conversion shall be at the rate of exchange thereafter published in the Wall Street Journal for the business day closest to the end of the applicable ACCOUNTING PERIOD. 
 6.4 With each semiannual payment, COMPANY shall deliver to GENERAL a full and accurate accounting. Such report shall be certified as correct by an
officer of COMPANY. 
 7. INFRINGEMENT 
 7.1 Each party shall inform the other promptly in writing of any alleged infringement of the PATENT RIGHTS by a third party, including all details then available. So long as the License is exclusive, COMPANY shall
have the right to prosecute in its own name and at its own expense any infringement of any patent within PATENT RIGHTS. 
 7.2 If COMPANY
elects to commence an action as described above, COMPANY shall bear all expenses related to such action and GENERAL shall cooperate fully with COMPANY in connection with any such action. COMPANY, at its option and expense, may join GENERAL as a
plaintiff. 
 7.3 COMPANY will consult with GENERAL with respect to any settlement, consent judgment or other voluntary final disposition of
any suit, but shall have the final authority with respect thereto, unless such action will result in the invalidation of the PATENT RIGHTS, in which event the prior written consent of GENERAL will be required, which GENERAL agrees will not be
unreasonably withheld. 
 7.4 Recoveries or reimbursements from infringement actions commenced by COMPANY pursuant to this Article VII shall
be distributed as follows: (a) COMPANY and GENERAL shall be reimbursed litigation expenses, including but not limited to reasonable attorneys’ fees; (b) GENERAL shall be reimbursed for any payments past due; and (c) any remaining
recoveries or reimbursements shall belong to COMPANY, unless the Note has been paid in cash, (in which event 75% thereof shall belong to COMPANY and 25% shall belong to GENERAL. 
 7.5 If COMPANY has not taken legal action or been successful in obtaining cessation of the infringement within one hundred and twenty (120) days of
written notification from GENERAL, GENERAL may prosecute such an infringement at its own expense. In such event, GENERAL shall control the action and shall distribute any recoveries or reimbursements as follows: (a) COMPANY and GENERAL shall be
reimbursed litigation expenses, including but not limited to reasonable attorneys’ fees; and (b) any remaining recoveries or reimbursements 

  

 9 

 
shall belong to GENERAL. With respect to the settlement of any infringement prosecuted by GENERAL, GENERAL will not agree to any settlement, consent judgment
or other voluntary final disposition of the suit without the prior written consent of COMPANY. 
 7.6 If a declaratory judgment alleging
invalidity or non-infringement of any of the patents in PATENT RIGHTS is brought against COMPANY or GENERAL, COMPANY shall have the right to control such action by written notice to GENERAL given within sixty (60) days of notice of the suit. If
COMPANY does not give such notice within sixty (60) days after such notice of commencement of that action, GENERAL may elect to take over the sole defense of the action at its sole expense. 
 7.7 In any infringement suit that either party brings to enforce the Patent Rights, the other party shall, at the request and expense of the party
bringing the suit, cooperate in all reasonable respects, including, to the extent possible, obtaining the testimony of its employees and making available physical evidence in the possession of that party. 
 8. INDEMNIFICATION 
 8.1 (a) COMPANY
shall indemnify, defend and hold harmless GENERAL and its trustees, officers, medical and professional staff, employees, and agents and their respective successors, heirs and assigns (the “Indemnitees”), against any liability, damage, loss
or expense (including reasonable attorney’s fees and expenses of litigation) incurred by or imposed upon the Indemnitees or any one of them in connection with any claims, suits, actions, demands or judgments arising out of any theory of product
liability (including, but not limited to, actions in the form of tort, warranty, or strict liability) concerning any product, process or service made, used or sold pursuant to any right or license granted to COMPANY under this Agreement. 

(b) COMPANY’S indemnification under (a) above shall not apply to any liability, damage, loss or expense to the extent that it is directly
attributable to the negligent activities, reckless misconduct or intentional misconduct of the Indemnitees. 
 (c) COMPANY agrees, at its own
expense to provide attorneys reasonably acceptable to the GENERAL to defend against any actions brought or filed against any party indemnified hereunder with respect to the subject of indemnity contained herein, whether or not such actions are
rightfully brought. 
 (d) This paragraph 8.1 shall survive expiration or termination of this Agreement. 
 8.2 (a) Beginning at such time as any such product, process or service is being commercially distributed or sold (other than for the purpose of obtaining
regulatory approvals) by COMPANY or by a COMPANY, affiliate or agent of COMPANY, COMPANY shall, at its sole cost and expense, procure and maintain commercial general liability insurance in amounts not less than $2,000,000 per incident and $2,000,000
annual aggregate and naming the Indemnitees as additional insureds. Such commercial general liability insurance shall provide (i) product liability coverage and (ii) broad form contractual liability coverage for COMPANY’S
indemnification under paragraph 8.1 of this Agreement. If COMPANY elects to self-insure all or part of the limits described above (including deductibles or retentions which are in excess of 

  

 10 

 
$250,000 annual aggregate) such self-insurance program must be acceptable to the GENERAL and the Risk Management Foundation. The minimum amounts of insurance
coverage required under this paragraph 8.2 shall not be construed to create a limit of COMPANY’S liability with respect to its indemnification under paragraph 8.1 of this Agreement. 
 (b) COMPANY shall provide GENERAL with written evidence of such insurance upon request of GENERAL. COMPANY shall provide GENERAL with written notice at
least fifteen (15) days prior to the cancellation, non-renewal or material change in such insurance; if COMPANY does not obtain replacement insurance providing comparable coverage prior to the expiration of such fifteen (15) day period,
GENERAL shall have the right to terminate this Agreement effective at the end of such fifteen (15) day period upon written notice but without any additional waiting periods. 
 (c) COMPANY shall maintain such commercial general liability insurance beyond the expiration or termination of this Agreement during (i) the period
that any such product, process, or service is being commercially distributed or sold (other than for the purpose of obtaining regulatory approvals) by COMPANY or by a COMPANY, affiliate or agent of COMPANY and (ii) a reasonable period after the
period referred to in (c) (i) above which in no event shall be less than fifteen (15) years. 
 (d) This paragraph 8.2 shall
survive expiration or termination of this Agreement. 
 8.3 OTHER THAN WARRANTIES SET FORTH HEREIN, GENERAL MAKES NO WARRANTY, EXPRESS OR
IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY OR ANY IMPLIED WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO ANY PATENT, TRADEMARK, SOFTWARE, TRADE SECRET, TANGIBLE RESEARCH PROPERTY, INFORMATION OR
DATA LICENSED OR OTHERWISE PROVIDED TO COMPANY HEREUNDER AND HEREBY DISCLAIMS THE SAME. 
 9. TERMINATION 
 9.1 Unless otherwise terminated as provided for in this Agreement, the license to PATENT RIGHTS granted hereunder will continue on a country by country
basis until the last to expire of any PATENT RIGHT, the claims of which but for this Agreement would be infringed by the manufacture, use or sale of any PRODUCT in the applicable country. 
 9.2 If either party shall fail to faithfully perform any of its obligations under this Agreement except the due diligence milestones specified in Article
3 herein, the nondefaulting party may give written notice of the default to the defaulting party. If said default is a financial default and it is not corrected within fifteen business (15) days after such notice, the notifying party may
terminate this Agreement and the license hereunder, unless the default is due to a bona fide dispute between the parties. For any other default, if the default is not cured within sixty (60) days of the written notice, or, if such default is
not able to be cured in sixty (60) days, the defaulting party is not utilizing diligent and continuous efforts to remedy such default, the notifying party may terminate this Agreement and the license hereunder. 
  

 11 

 9.3 In the event that any license granted to COMPANY under this Agreement is terminated, any sublicense
under such license granted prior to termination of said license shall remain in full force and effect, provided that: 
 (a) the SUBLICENSEE
is not then in breach of its sublicense agreement; and 
 (b) the SUBLICENSEE agrees to be bound to GENERAL as the licensor under the terms
and conditions of the sublicense agreement. 
 10. MISCELLANEOUS 
 10.1 This Agreement, together with the NOTE, constitutes the entire understanding between the parties with respect to the subject matter hereof.

 10.2 In order to facilitate implementation of this Agreement, GENERAL and COMPANY are designating the following individuals to act on
their behalf with respect to this Agreement for the matters indicated below: 
 (a) with respect to all payments, any correspondence
pertaining to any PATENT RIGHT, or any notice of the use of GENERAL’S name, for GENERAL, the Director, Corporate Sponsored Research and Licensing, and for COMPANY, the President; provided that correspondence relating to the billing of patent
costs shall be copied to, for GENERAL, the Business Manager, Corporate Sponsored Research and Licensing; and for COMPANY, the Chief Financial Officer. 
 (b) with respect to any amendment of or waiver under this Agreement, any written notice including progress reports or other communication pertaining to the Agreement: for GENERAL, the Director, Corporate Sponsored
Research and Licensing; and for COMPANY, the President. 
 (c) the above designations may be superseded from time to time by alternative
designations made by: for GENERAL, the President or the Senior Vice President for Research and Technology Affairs; and for COMPANY, the Chairman of the Board of Directors. 
 10.3 This Agreement may be amended and any of its terms or conditions may be waived only by a written instrument executed by the parties or, in the case
of a waiver, by the party waiving compliance. The failure of either party at any time or times to require performance of any provision hereof shall in no manner affect its rights at a later time to enforce the same. No waiver by either party of any
condition shall be deemed as a further or continuing waiver of such condition or term or of any other condition or term. 
 10.4 This
Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and their respective successors and permitted assigns. 
 10.5 Any delays in or failures of performance by either party under this Agreement shall not be considered a breach of this Agreement if and to the extent caused by occurrences 

  

 12 

 
beyond the reasonable control of the party affected, including but not limited to: Acts of God; acts, regulations or laws of any government; strikes or their
concerted acts of worker; fires; floods; explosions; riots; wars; rebellion; and sabotage. Any time for performance hereunder shall be extended by the actual time of delay caused by such occurrence. 
 10.6 Except as required by law or applicable regulation, neither party shall use the name of the other party or of any staff member, officer, employee or
student of the other party or any adaptation thereof in any advertising, promotional or sales literature, publicity or in any document employed to obtain funds or financing without the prior written approval of the party or individual whose name is
to be used, except that COMPANY may disclose the existence of this Agreement and the subject matter hereof. For GENERAL, such approval shall be obtained from GENERAL’s Chief Public Affairs Officer. 
 10.7 This Agreement shall be governed by and construed and interpreted in accordance with the laws of the Commonwealth of Massachusetts. 
 10.8 This Agreement shall not be assignable by GENERAL without COMPANY’S written consent except for the right to receive payments payable herein.
COMPANY may at its own discretion and without approval by GENERAL transfer its interest or any part thereof under this Agreement to a wholly-owned subsidiary or any assignee or purchaser of the portion of its business associated with the
development, manufacture and sale of PRODUCT or the surviving entity in any merger or consolidation. In the event of any such transfer, the transferee shall assume and be bound by the provisions of this Agreement. Otherwise this Agreement shall be
assignable by COMPANY only with the consent in writing of GENERAL. 
 10.9 For any and all claims, disputes, or controversies arising under,
out of, or in connection with this Agreement, except issues relating to the validity, construction or effect of any PATENT RIGHT, which the parties shall be unable to resolve within sixty (60) days, the party raising such dispute shall promptly
advise the other party of such claim, dispute, or controversy in a writing which describes in reasonable detail the nature of such dispute. By not later than five (5) business days after the recipient has received such notice of dispute, each
party shall have selected for itself a representative who shall have the authority to bind such party and shall additionally have advised the other party in writing of the name and title of such representative. By not later than ten
(10) business days after the date of such notice of dispute, such representatives shall agree upon a third party which is in the business of providing Alternative Dispute Resolution (ADR) services (hereinafter, “ADR Provider”) and
shall schedule a date with such ADR Provider to engage in ADR. Thereafter, the representatives of the parties shall engage in good faith in an ADR process under the auspices of the selected ADR Provider. If within the aforesaid thirty
(30) business days after the date of the notice of dispute the representatives of the parties have not been able to agree upon an ADR Provider and schedule a date to engage in ADR, or if they have not been able to resolve the dispute within
thirty (30) business days after the termination of ADR, the parties shall have the right to pursue any other remedies legally available to resolve such dispute in any court of competent jurisdiction. Notwithstanding the foregoing, nothing in
this Paragraph 10.9 shall be construed to waive any rights or timely performance of any obligations existing under this Agreement. 
  

 13 

 10.10 If any provision(s) of this Agreement are or become invalid, are ruled illegal by any court of
competent jurisdiction or are deemed unenforceable under then current applicable law from time to time in effect during the term hereof, it is the intention of the parties that the remainder of this Agreement shall not be effected thereby. It is
further the intention of the parties that in lieu of each such provision which is invalid, illegal or unenforceable, there be substituted or added as part of this Agreement a provision which shall be as similar as possible in economic and business
objectives as intended by the parties to such invalid, illegal or enforceable provision, but shall be valid, legal and enforceable. 
 REMAINDER OF PAGE INTENTIONALLY LEFT BLANK 
  

 14 

 THE PARTIES have duly executed this Agreement effective as of the date first shown above written.

  

									
	DARA PHARMACEUTICALS, INC.	 		 	THE GENERAL HOSPITAL CORPORATION
					
	BY:	 	  
	 		 	BY:	 	  

					
	TITLE:	 	CHAIRMAN OF THE BOARD	 		 	TITLE:	 	Director, CSRL

  

 15 

 Appendix A 
 PATENT RIGHTS 
 PATENT RIGHTS 
 MGH Case no. 1229 
 Patent No. 5,905,069 issued on
05/18/99 in the United States 
 Patent No. 758342 issued on 01/26/99 in Australia 
 Patent application no. 99802430.9 pending in China 
 Patent
application no. 2000-528292 pending in Japan 
 MGH Case no. 1725 
 Patent application no, 10/380,354 pending in the United States 
 PCT no. PCT/US01/29371 
 Patent application no. US01/29371 pending in Canada 
 Patent
application no. 0197122.3 pending in EPO 
  

 16 

 Appendix B 
 List of GENERAL Sponsors 
 MGH Case no. 1229 
 Kirin Brewery Company Limited 
  

 17Exclusive Lisence Agreement effective July 1, 2004

 EXHIBIT 10.10 
 CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR SUCH PORTIONS. ASTERISKS DENOTE OMISSIONS. 
 EXCLUSIVE LICENSE AGREEMENT 
 This Exclusive License Agreement (this “Agreement”) is made effective as of
July 1st, 2004 (the “Effective Date”) by and between Kirin Brewery Company, Limited, a
Japanese corporation with a principal place of business at 10-1 Shinkawa 2-chome, Chuo-ku, Tokyo 104-8288 Japan (hereinafter “Kirin”), and Dara Therapeutics, Inc., a Delaware corporation with a place of business at 1234 Airport Road, Suite
#105, Destin, FL 32541 (hereinafter “Dara”). Each of Kirin and Dara may be referred to hereinafter as a “Party” and together as the “Parties.” 
 WHEREAS, Kirin is the owner of or otherwise controls certain proprietary patents and technology relating to or otherwise useful in the production of
Licensed Product (defined below); and 
 WHEREAS, Dara desires to obtain the exclusive right from Kirin to develop and commercialize Licensed
Product in the Licensed Field (defined below) using such patents and technology; and 
 WHEREAS, Dara intends to conduct clinical trials of
Licensed Product in the Licensed Field and requires sufficient supply of Drug Product (defined below) therefor; and 
 WHEREAS, Kirin desires
to grant such rights and to supply, or assist in the supply by NCI of, Drug Substance (defined below) to Dara on the terms and conditions of this Agreement. 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties hereby agree as follows:

  

	 	1.	DEFINITIONS 

 Whenever used in the Agreement with an
initial capital letter, the terms defined in this Section 1 shall have the meanings specified. 
 1.1 “Adverse
Event” shall mean any untoward medical occurrence in a patient or subject who is administered a Licensed Product, whether or not considered related to a Licensed Product, including, without limitation, any undesirable sign (including
abnormal laboratory findings of clinical concern), symptom or disease temporally associated with the use of such Licensed Product. 
 1.2
“Affiliate” shall mean any corporation, firm, limited liability company, partnership or other entity that directly controls or is controlled by or is under common control with a Party to this Agreement. “Control”
for purposes of this Section 1.2 means ownership, directly or indirectly through one or more Affiliates, of fifty percent (50%) or more of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or
fifty percent (50%) or more of the equity interests in the case of any other type of legal entity, status as a 

 
general partner in any partnership, or any other arrangement whereby a Party controls or has the right to control the board of directors or equivalent
governing body of a corporation or other entity. 
 1.3 “BLA” shall mean a biologics license application (as defined
in Title 21 of the United States Code of Federal Regulations, as amended from time to time) filed with the FDA seeking Regulatory Approval to market and sell any Licensed Product in the United States for a particular indication within the Licensed
Field. 
 1.4 “Confidential Information” shall mean (a) with respect to a Party (the “Receiving
Party”), any and all information (including all Licensed Technology, to the extent not publicly disclosed in connection with the development or marketing of Licensed Product), which is disclosed by the other Party (the “Disclosing
Party”) to the Receiving Party hereunder or to any of its employees, consultants, Affiliates, licensees or Sublicensees, at any time and from time to time during the Term, except to the extent that the information described in this
Section 1.4, as shown by competent written documentation, (i) as of the date of disclosure is known to the Receiving Party or its Affiliates other than by virtue of a prior confidential disclosure to such Party or its Affiliates;
(ii) as of the date of disclosure is in, or subsequently enters, the public domain, through no fault or omission of the Receiving Party; (iii) is obtained from a Third Party having a lawful right to make such disclosure free from any
obligation of confidentiality to the Disclosing Party; or (iv) is independently developed by or for the Receiving Party without reference to or reliance upon any Confidential Information of the Disclosing Party. “Confidential
Information” shall include, without limitation, information relating to scientific, technical and economic information, business or research strategies, know-how, trade secrets, results of testing, and material embodiments thereof. 

1.5 “Control” or “Controlled” shall mean, with respect to any data, results, information, inventions,
know-how, formulas, trade secrets, techniques, methods, procedures, development, material or compositions of matter of any type or kind, whether or not patentable, or any intellectual property right, possession of the ability, whether by ownership
or license, to assign, grant a license, sublicense, immunities or other rights as provided for herein to such item or under such right without violating the terms of any agreement or other arrangement with any Third Party. 
 1.6 “CTA” shall have the meaning set forth in Schedule B attached hereto. 
 1.7 “Derivatives” shall mean the specific structures possessing a SAN backbone described in allowed composition of matter claims
of the Licensed Patent Rights. 
 1.8 “Dara Inventions” shall mean any pre-clinical and clinical data, invention or
discovery relating to the manufacture or use of Licensed Product created, identified, developed, conceived or reduced to practice solely by employees of or consultants to Dara, during the Term. 
 1.9 “Development” and “Develop” shall mean, with respect to any Licensed Product, all activities with
respect to such Licensed Product relating to research and development in connection with seeking, obtaining and/or maintaining any Regulatory Approval for such 

  

 2 

 
Licensed Product in the Licensed Field in the Territory, including without limitation, all pre-clinical research and development activities, all human
clinical studies, all activities relating to developing the ability to manufacture any Licensed Product or any component thereof (including, without limitation, process development work), and all other activities relating to seeking, obtaining
and/or maintaining any Regulatory Approvals from the FDA and/or any Foreign Regulatory Authority. 
 1.10 “Disclosing
Party” shall have the meaning set forth in Section 1.4 hereof. 
 1.11 “Drug Approval Application”
shall mean any application for Regulatory Approval (including pricing and reimbursement approvals) required prior to any commercial sale or use of a Licensed Product in any country or jurisdiction in the Territory, including, without limitation,
(a) any BLA or NDA filed with the FDA, and (b) any equivalent application filed with any Foreign Regulatory Authority for Regulatory Approval (including pricing and reimbursement approvals) required prior to any commercial sale or use of a
Licensed Product in any country or jurisdiction in the Territory. 
 1.12 “Drug Product” shall mean formulated Drug
Substance suitable for use in human clinical trials. 
 1.13 “Drug Substance” shall mean bulk active KRN5500.

 1.14 “FDA” shall mean the United States Food and Drug Administration and any successor agency or authority
thereto. 
 1.15 “First Commercial Sale” shall mean, on a country-by-country basis, the date of the first arm’s
length transaction, transfer or disposition for value to a Third Party of a Licensed Product by or on behalf of Dara or any Affiliate or Sublicensee in such country. 
 1.16 “Foreign Regulatory Authority” shall mean any applicable supranational, national, federal, state or local regulatory agency, department, bureau or other governmental entity of any country
or jurisdiction in the Territory (other than the FDA in the United States), having responsibility in such country or jurisdiction for any Regulatory Approvals of any kind in such country or jurisdiction, and any successor agency or authority
thereto. 
 1.17 “IND” shall mean an investigational new drug application (as defined in Title 21 of the United
States Code of Federal Regulations, as amended from time to time) filed or to be filed with the FDA with regard to any Licensed Product or the equivalent application to perform clinical trials filed or to be filed with any Foreign Regulation
Authority. 
 1.18 “Intermediates of KRN5500” shall mean SAN and TDG set forth in Section 1.32 and 1.36 hereof.

 1.19 “Know-how” shall mean any and all inventions, improvements, discoveries, claims, formulae, processed,
technologies and know-how (including Confidential Information) that generated, owned or Controlled by Kirin at any time before or during the term of this Agreement relating to, derived from or useful for the manufacture or use of the Licensed
Product, including, without limitation, synthesis, preparation, recovery and purification process and techniques, control methods and assays, chemical data and specifications. 
  

 3 

 1.20 “KRN5500” shall mean 6-[2-Deoxy-4-[(2E, 4E)
tetradecadienoylglycyl]amino-L-glycero-ß-L-mannoheptopyranosyl]amino-9H-purine; NSC number: NSC 650426. 
 1.21 “Licensed
Field” shall mean the treatment of pain and central and peripheral nervous system conditions or diseases. 
 1.22
“Licensed Patent Rights” shall mean any of the patents and patent applications listed on Schedule A attached hereto, any patents or patent applications claiming Know-how, and any divisional, continuation,
continuation-in-part, reissue, re-examination, renewal, revalidation, registration or extension or substitute thereof, or any patent issuing therefrom or any supplementary protection certificates, patents of addition or any foreign counterparts
related thereto. 
 1.23 “Licensed Product” shall mean any product (including without limitation KRN5500 and analogs
and derivates thereof) the manufacture, use or sale of which would, absent the license granted to Dara hereunder, infringe any Valid Claim included in the Licensed Patent Rights. 
 1.24 “Licensed Technology” shall mean and include the Technology listed on Schedule B attached hereto and all other
Technology Controlled by Kirin as of the Effective Date or during the Term, whether or not patentable, that is (i) related to any Valid Claim or is necessary or useful for the practice of the license granted to Dara hereunder or
(ii) necessary or useful for manufacturing KRN5500 and/or Licensed Product. 
 1.25 “NCI” shall mean the
National Cancer Institute. 
 1.26 “NDA” shall mean a new drug application (as defined in Title 21 of the United
States Code of Federal Regulations, as amended from time to time) filed with the FDA seeking Regulatory Approval to market and sell any Licensed Product in the United States for a particular indication within the Licensed Field. 
 1.27 “Net Sales” shall mean the gross invoiced sales price for all Licensed Product sold by Dara, its Affiliates or Sublicensees
to Third Parties throughout the Territory during each calendar quarter, less the following amounts incurred or paid by Dara or its Affiliates or Sublicensees during such calendar quarter with respect to sales of Licensed Product regardless of the
calendar quarter in which such sales were made: 
 (a) trade, cash and quantity discounts or rebates actually allowed or taken, including
discounts or rebates to governmental or managed care organizations; 
 (b) credits or allowances actually given or made for rejection of,
and for uncollectible amounts on, or return of previously sold Licensed Product (including Medicare and similar types of rebates); 
  

 4 

 (c) any charges for insurance, freight, and other transportation costs directly related to the delivery
of Licensed Product to the extent included in the gross invoiced sales price; 
 (d) any tax, tariff, duty or governmental charge levied on
the sales, transfer, transportation or delivery of a Licensed Product (including any tax such as a value added or similar tax or government charge) borne by the seller thereof, other than franchise or income tax of any kind whatsoever; and

 (e) any import or export duties or their equivalent borne by the seller. 
 “Net Sales” shall not include sales or transfers between Dara and its Affiliates or Sublicensees, unless the Licensed Product is consumed by the Affiliate or Sublicensee. In the event that a Licensed Product
under this Agreement is sold in combination with another active ingredient or component, then “Net Sales,” for purposes of determining royalty payments on the combination, shall be calculated using one of the following methods: 

 

	 	(i)	By multiplying the Net Sales of the combination by the fraction A/A+B, where A is the gross selling price, during the royalty paying period in question, of the Licensed Product sold
separately in similar quantities in the same country, and B is the gross selling price, during the royalty period in question, of the other active ingredients or components sold separately in similar quantities in the same country; or

  

	 	(ii)	In the event that no such separate sales are made of the Licensed Product or any of the active ingredients or components in such combination package in similar quantities in the
same country during the royalty paying period in question, Net Sales, for the purposes of determining royalty payments shall be calculated using the above formula where A is the reasonably estimated commercial value of the Licensed Product sold
separately in similar quantities in the same country and B is the reasonably estimated commercial value of the other active ingredients or components sold separately in similar quantities in the same country. Any such estimates shall be determined
using criteria to be mutually agreed upon by the Parties. Such estimates shall be reported to Kirin with the reports to be provided pursuant to Section 4.5.1 hereof. 

 1.28 “Phase II Clinical Trial” shall mean a clinical investigation (as defined in Title 21 of the United States Code of Federal
Regulations, as amended from time to time) conducted to evaluate the effectiveness of a License Product for a particular indication within the Licensed Field in patients with the disease or indication under study. 
  

 5 

 1.29 “Post Phase II Meeting” shall mean a meeting between Dara and the FDA
following completion of a Phase II Clinical Trial to test the safety and efficacy of a Licensed Product for a particular indication in the Licensed Field as a result of which Dara is authorized to proceed with a phase III clinical trial or to file a
Drug Approval Application. 
 1.30 “Receiving Party” shall have the meaning set forth in Section 1.4 hereof.

 1.31 “Regulatory Approval” shall mean any and all approvals (including pricing and reimbursement approvals),
product and establishment licenses, registrations or authorizations of any kind of the FDA or any Foreign Regulatory Authority necessary for the development, pre-clinical and/or human clinical testing, manufacture, quality testing, supply, use,
storage, importation, export, transport, marketing and sale of a Licensed Product (or any component thereof) for use in the Licensed Field in any country or other jurisdiction in the Territory. “Regulatory Approval” shall include, without
limitation, any Drug Approval Application 
 1.32 “SAN” shall mean
Spicamycinaminonucleoside—6-amino-[L-mannoheptopyranosyl]amino-9H-purine. 
 1.33 “Sublicense” shall mean an
agreement with a Third Party to whom Dara grants a sublicense of some or all of the rights granted to Dara pursuant to Section 2.1 hereof. 
 1.34 “Sublicensee” shall mean a Third Party to whom Dara grants a Sublicense. 
 1.35 “Sublicense
Royalty” shall have the meaning set forth in Section 4.3.2 hereof. 
 1.36 “TDG” shall mean
Tetradecadienoylglycine. 
 1.37 “Technology” shall mean and include any and all unpatented proprietary ideas,
inventions, discoveries, Confidential Information, biologic materials, data, results, formulae, designs, specifications, methods, processes, formulations, techniques, ideas, know- how, technical information (including, without limitation, structural
and functional information), process information, pre-clinical information, clinical information, and any and all proprietary biological, chemical, pharmacological, toxicological, pre-clinical, clinical, assay, control and manufacturing data and
materials. 
 1.38 “Term” shall have the meaning set forth in Section 8.1 hereof. 
 1.39 “Territory” shall mean all countries and jurisdictions of the world except Australia, New Zealand and all countries in Asia.

 1.40 “Third Party” shall mean any person or entity other than Dara, Kirin and their respective Affiliates.

 1.41 “Third Party Payments” shall have the meaning set forth in Section 4.3.4 hereof. 
  

 6 

 1.42 “Valid Claim” shall mean a claim of any issued unexpired patent within the
Licensed Patent Rights that has not been held unenforceable, unpatentable or invalid by a decision of a court or governmental body of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been
rendered unenforceable through disclaimer or otherwise or which has not been lost through an interference proceeding. 
  

	 	2.	GRANT OF RIGHTS 

 2.1 License to Dara.

 2.1.1 Grant of License. Kirin hereby grants to Dara an exclusive, royalty-bearing license, including the right to grant sublicenses
in accordance with Section 2.1.3 below, under the Licensed Patent Rights, Licensed Technology and Know-how to research, Develop, have Developed, manufacture, have manufactured, use, have used, sell, offer for sale, have sold, import, have
imported, export and have exported, Licensed Product in the Territory, for any and all uses within the Licensed Field, subject to the terms and conditions of this Agreement. 
 2.1.2 NCI Consents. The grant of the license in Section 2.1.1 above with respect to any Licensed Technology owned by NCI is subject to Dara
obtaining any required consent or agreement from NCI. Kirin will cooperate with Dara to obtain such consent or agreement, but Kirin does not guaranty that NCI will give such consent or agreement. 
 2.1.3 Right to Sublicense. Dara shall have the right to grant sublicenses to all or any portion of its rights under the license granted pursuant
to Section 2.1.1 above to any Third Party; provided, however, that Kirin shall be notified of any and all executed Sublicenses. 
 2.2 Dara Inventions 
 2.2.1 Ownership. Dara shall solely own all right, title and interest in the Dara
Inventions. 
 2.2.2 Option. Dara hereby offers to Kirin an exclusive option, on a country-by-country basis (each, an
“Option”), for an exclusive royalty-free license (each, an “Extra-Territorial License”), with the right to grant sublicenses, under the Dara Inventions and/or any patent application or patent Controlled by Dara that claims the
Dara Inventions to develop, manufacture, have manufactured, use, have used, sell, offer for sale, have sold, import, have imported, export and have exported, Licensed Product in the Licensed Field, for any country outside the Territory during the
Term. Kirin shall exercise the Option by providing written notice to Dara during the Term of its intent to exercise such Option, provided, however, at any time during the Term, Dara may provide notice to Kirin that it intends to grant
to a Third Party an Extra-Territorial License in a country or countries in which no Option has been exercised, which notice shall contain the terms to be offered to such Third Party. Kirin shall have sixty (60) days (the “Option
Period”) following receipt of such notice to exercise the Option and enter into good faith negotiations with Dara. If Kirin provides written notice of its intent not to exercise the Option or upon expiration of the Option Period, Dara shall
have the right to grant such Extra-Territorial license to any Third Party on the terms provided in the notice without any further obligation to Kirin with regard thereto. 
  

 7 

	 	3.	DEVELOPMENT AND COMMERCIALIZATION OF LICENSED PRODUCT; SUPPLY AND MANUFACTURE OF KRN5500. 

 3.1 Commercialization. 
 3.1.1
Responsibility. On and after the Effective Date, Dara shall have full control and authority over all Development and commercialization of Licensed Product in the Licensed Field in the Territory including, without limitation, (a) all
activities relating to manufacture and supply of all Licensed Product (including all required process development and scale up work with respect thereto), (b) all marketing, promotion, sales, distribution, import and export activities relating
to any Licensed Product, and (c) all activities relating to any regulatory filings, registrations, applications and Regulatory Approvals relating to any of the foregoing. Dara shall own all data, results and all other information arising from
any such activities under this Agreement, including without limitation, all regulatory filings, registrations, applications and Regulatory Approvals relating to Licensed Product including, without limitation, any INDs and any Drug Approval
Applications, and all of the foregoing information, documentation and materials shall be considered Confidential Information and Technology solely owned by Dara. All activities relating to Development and commercialization under this Agreement shall
be undertaken at Dara’s sole cost and expense, except as otherwise expressly provided in this Agreement. 
 3.1.2 Diligence.
Dara will exercise commercially reasonable efforts and diligence in developing and commercializing Licensed Product in the Licensed Field in the Territory, such reasonable efforts and diligence to be in accordance with the efforts and resources Dara
would use for a product candidate owned by it or to which it has rights, which is of similar market potential as the applicable Licensed Product, taking into account the competitiveness of the marketplace, the proprietary position of the Licensed
Product, the relative potential safety and efficacy of the Licensed Product, the cost of goods and availability of capacity to manufacture and supply the Licensed Product at commercial scale, the profitability of the applicable Licensed Product, and
other relevant factors including, without limitation, technical, legal, scientific or medical factors. 
 3.2 Updates and
Reports. 
 3.2.1 Updates and Reports. Dara shall provide Kirin with brief written reports no less frequently than annually
during the Term (commencing with the first anniversary of the Effective Date) summarizing (i) Dara’s material efforts to develop and commercialize all Licensed Product hereunder and (ii) any Dara Invention made during the period since
the last such report. In addition, Dara shall provide Kirin with prompt written notice of the occurrence of the First Commercial Sale of any Licensed Product. 
 3.2.2 Adverse Events. Upon execution of a disclosure agreement between Dara and NCI, Dara may reference NCI’s clinical data of Licensed Product including but not limited to Adverse Events and Serious
Adverse Events Reports, pharmacokinetic and pharmacodynamic data, and relevant correspondence with the FDA. Kirin will provide 

  

 8 

 
reasonable assistance as is reasonably requested by Dara. Additionally, subject to Kirin’s exercise of an Option pursuant to Section 2.2.2 hereof,
the Parties agree to provide each other with Adverse Event information and product complaint information relating to the relevant Licensed Product as compiled and prepared by each Party in the normal course of business in connection with the
Development and commercialization of the relevant Licensed Patent Rights, within time frames consistent with reporting obligations under applicable laws and regulations. 
 3.2.3 All reports, updates, Adverse Event, product complaint and other information provided by one Party to the other Party under this Agreement (including under this Section 3), shall be considered Confidential
Information of the disclosing Party, subject to the terms of Section 5. 
 3.3 KRN5500 Supply. 
 3.3.1 Supply of KRN5500. Within fourteen (14) days of Dara’s written request, Kirin will provide 200g of Drug Substance from Lot SK032
(the “Lot SK032 Material”). Dara agrees to retest, at Dara’s sole expense, the stability of the Lot SK032 Material at Midwest Research Institute (“MRI”), or another subcontractor of Dara’s choosing, prior to use in
clinical trials. If, in Dara’s sole discretion, the Lot SK032 Material meets release specifications and is suitable for use in clinical trials, Dara may choose to use the Lot SK032 Material to manufacture Drug Product at Ben Venue Laboratories,
or another subcontractor of Dara’s choosing. In parallel, Dara will use commercially reasonable efforts to obtain 25g of Drag Substance from Lot SK030 (the “Lot SK030 Material”) from the NCI. Dara agrees to retest the stability of any
Lot SK030 Material received from NCI at MRI, or another subcontractor of Dara’s choosing, prior to use in clinical trials, at Dara’s sole expense. Pursuant to the CTA, Kirin has granted consent to the NCI to supply Drug Product and Drug
Substance to Dara. Kirin agrees to help facilitate this supply process, if reasonably required. If, in Dara’s sole discretion, the Lot SK030 Material meets release specifications and is suitable for use in clinical trials, Dara may choose to
use the Lot SK030 Material to manufacture Drug Product at Ben Venue Laboratories or another subcontractor of Dara’s choosing. If Dara judges any Lot SK032 Material or Lot SK030, for any reason, to be unacceptable for use in clinical trials or
if there is insufficient quantities of Lot SK032 Material or Lot SK030 Material to complete the clinical trials undertaken by Dara, Kirin grants Dara the right to manufacture additional quantities of Drug Substance from Kirin’s stockpile of raw
materials and intermediates stored at Starks Associates, Inc. or elsewhere. 
 3.3.2 Spicamycin and Derivatives Supply. Within thirty
(30) days of Dara’s written request, Kirin shall supply, at no charge, reasonable quantities of SAN and TDG currently in Kirin’s inventory in order to facilitate Dara’s medicinal chemistry initiative to synthesize new Spicamycin
analogues and Derivatives. 
 3.3.3 Nothing herein shall preclude Dara from making its own arrangements for the manufacture and supply of
Drug Product, Drug Substance, intermediates for KRN5500, SAN, TDG, Spicamycin or any Derivatives on its own or with Third Parties. Dara hereby agrees that it shall use KRN5500 in compliance with all applicable federal, state and local laws.

  

 9 

 3.4 Technology Transfer. 
 3.4.1 With fourteen (14) days of the Effective Date, Kirin shall provide to Dara all Know-how and process information Controlled by Kirin for
manufacturing Drug Product from Drug Substance. 
 3.4.2 Within thirty (30) days of completion of a Phase II Clinical Trial, the
results of which are sufficiently satisfactory to Dara to justify conducting Phase III trials, Kirin shall provide to Dara a reasonable quantity of viable cell line from working and master cell banks previously used to produce Spicamycin and shall
provide to Dara all Technology Controlled by Kirin as of such date that is necessary for or useful in the manufacture of Drug Substance. 
 3.4.3 At such times during the Term as Dara shall request, Kirin shall also provide technical assistance as is reasonably requested by Dara, or its Sublicensees, in order to manufacture Drug Product and Drug Substance as contemplated under
this Agreement. After completion of a Phase II Clinical Trial, the results of which are sufficiently satisfactory to Dara to justify conducting phase III clinical trials, Kirin’s assistance shall include reasonably requested visits by qualified
representatives of Kirin, to Dara’s or its Sublicensees’ manufacturing facilities for the purpose of validating Drug Product and/or Drug Substance manufacturing process conducted at such facilities. 
 3.5 Commercial Supply. At the request of Dara, the Parties will negotiate in good faith a commercial supply agreement; provided,
however, neither Party shall be obligated to enter into it. 
  

	 	4.	PAYMENTS AND ROYALTIES 

 4.1 Upfront
Fee. In consideration of the grant of the license by Kirin hereunder, Dara hereby agrees to pay Kirin an upfront license fee in the amount of [***] payable within thirty (30) days of execution of this Agreement, which payment shall be
nonrefundable and noncreditable. 
 4.2 Milestone Payments. 
 4.2.1 Payment. In consideration of inclusion of access to Kirin’s pre-clinical and clinical data, Kirin’s provision of Know-how,
Kirin’s supply of Drug Substance, and the grant of the license by Kirin hereunder and subject to the other terms and conditions of this Agreement, Dara shall make the following nonrefundable, noncreditable payments to Kirin within thirty
(30) days of the first occurrence of each of the following events by Dara or an Affiliate or Sublicensee: 
  

			
	 Milestone
	  	Payment
	 Submission to, and acceptance by, the applicable regulatory authority
	  	[***]
	 (after any required waiting period) of an IND (or foreign equivalent) for a
	  	
	 Licensed Product
	  	
	 Post Phase II Meeting
	  	[***]

  

 10 

 It is hereby acknowledged and agreed that any milestone payment shall be made only once, with respect to the first
achievement of the relevant milestone for the first Licensed Product, regardless of how many times such milestones are achieved by Licensed Product and regardless of how many times a particular Licensed Product achieves such milestones. 

4.3 Payment of Royalties 
 4.3.1 Royalty Payments In further consideration of the grant of the license by Kirin hereunder, and subject to the other terms of this Agreement (including the remainder of this Section 4.3), commencing on the date of the First
Commercial Sale of any Licensed Product and for the remainder of the Term, Dara shall pay to Kirin a royalty equal to [***] of Net Sales of any Licensed Product sold by Dara or its Affiliates in the Territory. 
 4.3.2 Sublicense Royalties. In addition to all other fees set forth above, and subject to the other terms of this Agreement (including the
remainder of this Section 4.3), Dara shall pay to Kirin an amount equal to [***]. 
 4.3.3 One Royalty. Only one royalty,
calculated at the highest applicable royalty rate under this Section 4.3, shall be payable to Kirin hereunder for each sale of a Licensed Product. 
 4.3.4 Third Party Royalty Offset. If in any period in which royalties or Sublicense Royalties are due, Dara, its Affiliates or Sublicensees actually make royalty payments to one or more Third Parties
(“Third Party Payments”) as consideration for a license to any patent application or issued patent claiming the Development, manufacture, use, sale, import, or export of Licensed Product, then Dara shall have the right to reduce the
royalties or Sublicense Royalties, as the case may be, otherwise due to Kirin pursuant to this Section 4.3 for such Licensed Product by [***] of the full amount of such Third Party Payments during the same period. Notwithstanding the foregoing,
such reductions shall in no event reduce such royalties or Sublicense Royalties, as the case may be, for such Licensed Product in any such country to less than [***] of the rates otherwise specified in this Section 4.3. In no event shall any
reduction pursuant to this Section 4.3.4 be available with regard to royalties due for a license from The General Hospital Corporation under its intellectual property rights in Patent Application No. PCT US0129371, Publication No. WO02-24146
and in U.S. Patent No. 5,905,069. 
 4.4 Payment Terms. 
 4.4.1 Payment of Royalties. Dara shall deliver to Kirin a written report on any royalty or Sublicense Royalty, within forty-five (45) days
from the end of each quarter in such payment accrues, specifying: the gross sales (if available) and Net Sales in the applicable 

  

 11 

 
currency; the applicable royalty rate under this Agreement; the royalties payable in each currency, including an accounting of deductions taken in the
calculation of Net Sales and any applicable calculation pursuant to Section 4.3.4 hereof; the applicable exchange rate to convert from each country’s currency to United States Dollars under this Section 4.4. For purposes of
determining when a sale of any Licensed Product occurs under this Agreement, royalties shall accrue on the date of the invoice to the purchaser of the Licensed Product. Dara shall make any royalty or Sublicense Royalty payments owed to Kirin
hereunder in arrears, within sixty (60) days from the end of each quarter in which such payment accrues. 
 4.4.2 Overdue
Royalties. Subject to the other terms of this Agreement, royalties not paid within the time period set forth in this Section 4 shall bear interest at a rate of [***] per month from the due date until paid in full. 
 4.4.3 Accounting. All payments hereunder shall be made in United States dollars by wire transfer of immediately available funds in accordance
with the wiring instructions furnished by Kirin in writing. Conversion of foreign currency to U.S. dollars shall be made at the conversion rate existing in the United States (as reported in The Wall Street Journal) on the last business day of
the calendar quarter for which the royalties are paid. If The Wall Street Journal ceases to be published, then the rate of exchange to be used shall be that reported in such other business publication of national circulation in the United
States as the Parties reasonably agree. Dara shall deduct any taxes that it is obligated to pay and/or withhold on the payments due under this Agreement and pay them to the proper authorities as required by applicable laws. Therefore, it is agreed
and understood that any amount to be paid under the terms of this Agreement is net of any such tax. Dara shall maintain official receipts of payment of any such taxes and forward these receipts to Kirin within sixty (60) days and shall provide
reasonable assistance to Kirin in obtaining any credit or refund of such taxes. 
 4.5 Records Retention; Review. 

4.5.1 Records. Commencing as of the date of the First Commercial Sale of the first Licensed Product, Dara and its Affiliates and Sublicensees
shall keep for at least three (3) years from the end of the calendar year to which they pertain complete and accurate records of sales by Dara, its Affiliates or Sublicensees, as the case may be, of each Licensed Product, in sufficient detail
to allow the accuracy of the payments hereunder to be confirmed. 
 4.5.2 Review. Subject to the other terms of this
Section 4.5.2, at the request of Kirin (which shall not be made more frequently than once per calendar year during the Term), upon at least thirty (30) days’ prior written notice from Kirin, and at the expense of Kirin (except as
otherwise provided herein), Dara shall permit an independent certified public accountant reasonably selected by Kirin and reasonably acceptable to Dara to inspect (during regular business hours) the relevant records required to be maintained by Dara
under this Section 4.5 for the then-preceding three (3) years for purposes of verifying Dara’s royalty calculations. In every case the accountant must have previously entered into a confidentiality agreement with Dara, or with Kirin
and naming Dara as a third party beneficiary thereof, substantially similar to the provisions of Section 5 and limiting the disclosure and use of such information by such accountant to authorized representatives of the Parties and the purposes
germane to this Section 4.5. No other information shall be shared. Results of any such review 

  

 12 

 
shall be binding on both Parties absent manifest error. Kirin agrees to treat the results of any such accountant’s review of Dara’s records under
this Section 4.5 as Confidential Information of Dara subject to the terms of Section 5 hereof. If any review reveals a deficiency in the calculation of royalties resulting from any underpayment by Dara, Dara shall promptly pay Kirin the
amount remaining to be paid, and if such underpayment is by ten percent (10%) or more, Dara shall pay the reasonable out-of-pocket costs and expenses of the review. 
 4.5.3 Other Parties. Dara shall include in any agreement with its Affiliates or Sublicensees record retention and record review terms substantially similar to those in Section 4.5.2 above. Subject to the
other terms of such agreement, at the request of Kirin (which shall not be made more frequently than once per calendar year during the Term), upon at least thirty (30) days’ prior written notice from Kirin, and at the expense of Kirin,
Dara shall inspect or have a Third Party inspect, such Affiliate’s or Sublicensee’s records. 
  

	 	5.	TREATMENT OF CONFIDENTIAL INFORMATION 

 5.1
Confidential Obligations. Kirin and Dara each recognize that the other Party’s Confidential Information constitutes highly valuable and proprietary confidential information. Kirin and Dara each agree that during the Term and for
five (5) years thereafter, it will keep confidential, and will cause its employees, consultants, Affiliates and Sublicensees to keep confidential, all Confidential Information of the other Party. Neither Kirin nor Dara nor any of their
respective employees, consultants, Affiliates or Sublicensees shall use Confidential Information of the other Party for any purpose whatsoever other than exercising any rights granted to it or reserved by it hereunder. Without limiting the
foregoing, each Party may disclose information to the extent such disclosure is reasonably necessary in (i) filing and prosecuting patent applications and maintaining patents which are filed in accordance with the provisions of this Agreement,
(ii) granting Sublicenses permitted hereunder, (iii) filing, prosecuting or defending litigation in accordance with the provisions of this Agreement or (iv) complying with applicable laws, regulations or court orders; provided,
however, that if a Party is required to make any such disclosure of the other Party’s Confidential Information other than to a Third Party that agrees in writing to maintain the confidentiality of such Confidential Information, it will give
reasonable advance notice to the other Party of such disclosure requirement and will use reasonable efforts to assist such other Party in efforts to secure confidential treatment of such information required to be disclosed. Confidential Information
of Kirin shall include, without limitation, “INFORMATION” as defined in that certain Confidentiality Agreement between the Parties dated September 26, 2002. 
 5.2 Limited Disclosure and Use. Kirin and Dara each agree that any disclosure of the other Party’s Confidential Information to any
officer, employee, consultant or agent of the other Party or any of its Affiliates or Sublicensees shall be made only if and to the extent necessary to carry out its rights and responsibilities under this Agreement, shall be limited to the maximum
extent possible consistent with such rights and responsibilities and shall only be made to persons who are bound by written confidentiality obligations to maintain the confidentiality thereof and not to use such Confidential Information except as
expressly permitted by this Agreement. Kirin and Dara each further agree not to disclose or transfer the other Party’s Confidential Information to any Third Parties under any circumstance without the prior written approval from the other Party
(such approval not to be unreasonably withheld), 

  

 13 

 
except either Party may without such approval disclose Confidential Information of the other Party to: (i) a Sublicensee or prospective Sublicensee
solely in connection with the exercise of such Party’s rights under this Agreement, or a Third Party in connection with an actual or potential investment, loan, financing, merger or acquisition transaction with such Party; provided, that such
Sublicensee, prospective Sublicensee or Third Party has undertaken in writing an obligation of confidentiality with respect to the Confidential Information substantially similar to that provided herein, (ii) as otherwise required by law, or
(iii) as otherwise expressly permitted by this Agreement. Each Party shall take such action, and shall cause its Affiliates or Sublicensees to take such action, to preserve the confidentiality of each other’s Confidential Information as it
would customarily take to preserve the confidentiality of its own Confidential Information, and in no event, less than reasonable care. Each Party, upon the request of the other Party, will return all the Confidential Information disclosed or
transferred to it by the other Party pursuant to this Agreement, including all copies and extracts of documents and all manifestations in whatever form, within sixty (60) days of the request or, if earlier, the termination or expiration of this
Agreement; provided however, that a Party may retain Confidential Information of the other Party relating to any license or right to use Licensed Technology which survives such termination and one copy of all other Confidential
Information may be retained in inactive archives solely for the purpose of establishing the contents thereof. 
  

	 	6.	PROVISIONS CONCERNING THE FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS 

 6.1 Patent Maintenance. Subject to the other terms of this Section 6.1, Kirin shall be responsible for preparing, filing and maintaining, at its sole cost, expense and discretion all Licensed Patent
Rights. Kirin will keep Dara reasonably informed of the status of all such filings and maintenance, including, without limitation, (A) by providing Dara with copies of all communications received from or filed in patent office(s) with respect
to such filings, and (B) by providing Dara, a reasonable time prior to taking or failing to take any action that would affect the scope or validity of any such filing (including the substantially narrowing, cancellation or abandonment of any
claim(s) without retaining the right to pursue such subject matter in a separate application, or the failure to file or perfect the filing of any claim(s) in any country), with prior written notice of such proposed action or inaction so that Dara
has a reasonable opportunity to review and comment. If Kirin fails to undertake the filing(s) of any patent submission with respect to any claim under the Licensed Patent Rights, then not less than ninety (90) days prior to the last date for
making the applicable filing or submission to preserve rights under such patent, Dara may undertake such filing(s) at its own expense, in Kirin’s name. 
 6.2 Notice of Infringement. If, during the Term, either Party learns of any actual, alleged or threatened infringement by a Third Party of any Licensed Patent Rights in the Licensed Field in the
Territory, such Party shall promptly notify the other Party and shall provide such other Party with available evidence of such infringement. 
 6.3 Infringement of Patent Rights. In the event of an actual, alleged or threatened infringement by a Third Party of any Licensed Patent Rights, the Parties shall mutually agree on the action to be taken to stop such
infringement; provided, however, Kirin shall have the first right (but not the obligation), at its own expense and with legal counsel of its own choice, to bring suit (or take other appropriate legal action) against any actual, alleged or 

  

 14 

 
threatened infringement of the Licensed Patent Rights in the Licensed Field. If Kirin does not file any action or proceeding against such infringement within
six (6) months after the later of (i) Kirin’s notice to Dara under Section 6.2 above, (ii) Dara’s notice to Kirin under Section 6.2 above, or (iii) a written request from Dara to take action with respect to
such infringement, then the Parties shall in good faith and in a timely manner discuss the appropriate legal action to stop such infringement, but if the Parties do no agree on another course of action, Dara shall, subject to Kirin’s approval,
which approval shall not be unreasonably withheld, have the right (but not the obligation), at its own expense, to bring suit (or take other appropriate legal action) against such actual, alleged or threatened infringement, with legal counsel of its
own choice, but shall not be permitted to settle any such suit without the prior consent of Kirin, which consent shall not be unreasonably withheld. Any damages, monetary awards or other amounts recovered, whether by judgment or settlement, pursuant
to any suit, proceeding or other legal action taken under this Section 6.3, shall applied as follows: 
 (a) First, to reimburse the
Parties for their respective costs and expenses (including reasonable attorneys’ fees and costs) incurred in prosecuting such enforcement action; 
 (b) Second, to Dara in reimbursement for lost sales (net of royalties) associated with Licensed Product and to Kirin in reimbursement for lost royalties owing hereunder based on such lost sales; 
 (c) Third, any amounts remaining shall be allocated as follows: (a) if Kirin is the Party bringing such suit or proceeding or taking such other
legal action, one hundred percent (100%) to Kirin, (b) if Dara is the Party bringing such suit or proceeding or taking such other legal action, one hundred percent (100%) to Dara, and (c) if the suit is brought jointly, fifty
percent (50%) to each Party. 
 If a Party brings any such action or proceeding hereunder, the other Party agrees to be joined as party
plaintiff if necessary to prosecute such action or proceeding, and to give the Party bringing such action or proceeding reasonable assistance and authority to file and prosecute the suit; provided, however, that neither Party shall be required to
transfer any right, title or interest in or to any property to the other Party or any Third Party to confer standing on a Party hereunder. 
  

	 	7.	REPRESENTATIONS AND WARRANTIES 

 7.1 Kirin
Representations. Kirin represents and warrants to Dara that: 
 (a) the execution and delivery of this Agreement and the performance
of the transactions contemplated hereby have been duly authorized by all appropriate Kirin corporate action; 
 (b) this Agreement is a
legal and valid obligation binding upon Kirin and enforceable in accordance with its terms, and the execution, delivery and performance of this Agreement by the Parties does not conflict with any agreement, instrument or understanding to which Kirin
is a party or by which it is bound; 
  

 15 

 (c) Kirin has the full right and legal capacity to grant the rights to Dara pursuant to Section 2
above without violating the rights of any Third Party; 
 (d) Kirin is the sole owner or exclusive licensee of the Licensed Technology other
than Licensed Technology identified as belonging to NCI; 
 (e) the Licensed Patents are the only patent applications or patents Controlled
by Kirin that claim Licensed Product or the use thereof; 
 (f) Kirin is not aware of any Third Party patent, patent application or other
intellectual property rights that would be infringed (i) by practicing any process or method or by making, using or selling any composition which is claimed or disclosed in, or which constitutes, Licensed Technology, or (ii) by making,
using, offering for sale, selling or importing Licensed Product; and 
 (g) Kirin is not aware of any actual or threatened infringement by
any Third Party of the Licensed Patents in the Licensed Field. 
 7.2 Dara Representations. Dara represents and warrants to
Kirin that: 
 (a) the execution and delivery of this Agreement and the performance of the transactions contemplated hereby have been duly
authorized by all appropriate Dara corporate action; and 
 (b) this Agreement is a legal and valid obligation binding upon Dara and
enforceable in accordance with its terms, and the execution, delivery and performance of this Agreement by the Parties does not conflict with any agreement, instrument or understanding to which Dara is a party of or by which it is bound. 

7.3 No Warranties. 
 Nothing in this Agreement is or shall be construed as: 
 (a) a warranty or representation by either Party as to the validity or
scope of any patent application or patent licensed hereunder; 
 (b) a warranty or representation that anything made, used, sold or
otherwise disposed of under any license granted pursuant to this Agreement is or will be free from infringement of patents, copyrights, and other rights of Third Parties. 
 7.4 Disclaimer. Except as expressly set forth in this Agreement, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR OF NON-INFRINGEMENT OF ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER RIGHTS OF THIRD PARTIES, OR ANY OTHER EXPRESS OR IMPLIED WARRANTIES. 
  

 16 

	 	8.	TERM AND TERMINATION 

 8.1 Term;
Expiration. The term of this Agreement (“Term”) shall commence upon the Effective Date and shall continue, unless terminated earlier pursuant to this Section 8, until the later of (a) the last to expire Valid Claim or
(b) seven (7) years from the date of the First Commercial Sale of the first Licensed Product. Upon the expiration of the Term of this Agreement, Dara shall have a fully paid-up, irrevocable, freely transferable and sublicensable license
under the Licensed Patent Rights and Licensed Technology, to Develop, have Developed, make, have made, use, have used, sell, have sold, offer for sale, import and have imported any and all Licensed Product for any and all uses in the Licensed Field,
in the Territory. 
 8.2 Termination for Breach. Subject to the other terms of this Agreement, this Agreement and the rights
and options granted herein may be terminated by either Party upon any material breach by the other Party of any material obligation or condition, effective ninety (90) days after giving written notice to the breaching Party of such termination,
which notice shall describe such breach in reasonable detail. The foregoing notwithstanding, if such default or breach is cured or remedied or shown to be non-existent within the aforesaid ninety (90) day period, the notice shall be
automatically withdrawn and of no effect. However, prior to giving any notice for breach, the Parties shall first attempt to resolve any disputes as to the existence of any breach as set forth in Section 9 hereof. 
 8.3 Effects of Termination. 
 8.3.1 Termination by Kirin. Upon any termination of this Agreement by Kirin under Section 8.2 above, as of the effective date of such termination, all relevant licenses and sublicenses granted by Kirin to Dara hereunder shall
terminate automatically. Notwithstanding the foregoing, (a) no such termination of this Agreement shall be construed as a termination of any valid Sublicense hereunder, and thereafter each such Sublicensee shall be considered a direct licensee
of Kirin, provided that (i) such Sublicensee is then in full compliance with all terms and conditions of its sublicense, and (ii) such Sublicensee agrees in writing to assume all applicable obligations of Dara under this Agreement, and
(b) Dara and its Affiliates and Sublicensees shall have the right, for six (6) months or such longer time period (if any) on which the Parties mutually agree in writing, to sell or otherwise dispose of all Licensed Product then on hand,
with royalties to be paid to Kirin on all Net Sales of such Licensed Product as provided for in this Agreement. 
 8.4
Remedies. Except as otherwise expressly set forth in this Agreement, the termination provisions of this Section 8 are in addition to any other relief and remedies available to either Party at law. 
 8.5 Surviving Provisions. Notwithstanding any provision herein to the contrary, the rights and obligations of the Parties set forth in
Sections 1, 5, 7, 8.3, 8.5, 9, and 10.3 as well as any rights or obligations otherwise accrued hereunder (including any accrued payment obligations), shall survive the expiration or termination of the Term. Without limiting the generality of the
foregoing, Dara shall have no obligation to make any milestone or royalty payment to Kirin that has not accrued prior to the effective date of any termination of this Agreement, but shall remain liable for all such payment obligations accruing prior
to the effective date of such termination. 
  

 17 

	 	9.	DISPUTES 

 9.1 The Parties recognize that a bona
fide dispute as to certain matters may from time to time arise during the Term that relates to either Party’s rights and/or obligations hereunder. In the event of the occurrence of such a dispute, either Party may, by written notice to the
other Party, have such dispute referred to their respective senior officials designated below or their successors, for attempted resolution by good faith negotiations within thirty (30) days after such notice is received. Said designated senior
officials are as follows: 
  

			
	For Dara:	 	Chief Executive Officer
	For Kirin:	 	Vice President, Planning Department, Pharmaceutical Division

 In the event the designated senior officials are not able to resolve such dispute within the
thirty (30) day period, either Party may invoke the provisions of Section 9.2. 
 9.2 Any dispute, controversy or claim initiated
by either Party arising out of, resulting from or relating to this Agreement, or the performance by either Party of its obligations under this Agreement (other than bona fide Third Party actions or proceedings filed or instituted in an action or
proceeding by a Third Party against a Party), whether before or after termination of this Agreement, shall be finally resolved by binding arbitration. Whenever a Party shall decide to institute arbitration proceedings, it shall give written notice
to that effect to the other Party. Any such arbitration shall be held in London, England in accordance with the then-prevailing Rules of Conciliation and Arbitration of the International Chamber of Commerce by a panel of three arbitrators appointed
in accordance with such rules. The method and manner of discovery in any such arbitration proceeding shall be governed by the laws of England. The arbitrators shall have the authority to grant injunctions and/or specific performance and to allocate
between the Parties the costs of arbitration in such equitable manner as they determine. Judgment upon the award so rendered may be entered in any court having jurisdiction or application may be made to such court for judicial acceptance of any
award and an order of enforcement, as the case may be. Notwithstanding the foregoing, either Party shall have the right, without waiving any right or remedy available to such Party under this Agreement or otherwise, to seek and obtain from any court
of competent jurisdiction any interim or provisional relief that is necessary or desirable to protect the rights or property of such Party, pending the selection of the arbitrators hereunder or pending the arbitrators’ determination of any
dispute, controversy or claim hereunder. 
  

 18 

	 	10.	MISCELLANEOUS 

 10.1 Notification. All
notices, requests and other communications hereunder shall be in writing, shall be addressed to the receiving Party’s address set forth below or to such other address as a Party may designate by notice hereunder, and shall be either
(i) delivered by hand, (ii) made by facsimile transmission (to be followed with written fax confirmation), (iii) sent by private courier service providing evidence of receipt, or (iv) sent by registered or certified mail, return
receipt requested, postage prepaid. The addresses and other contact information for the Parties are as follows: 
  

			
	If to Kirin:	  	 Katsuhiko Asano, Ph.D.
 Managing Executive Officer

 President of Pharmaceutical Division
 Kirin Brewery Company,
Limited
 26-1, Jingumae 6-chome,
 Shibuya-ku, Tokyo
150-8011
 Japan
 Phone: +81-3-5485-6207
 Fax: +81-3-3499-6152

		
	If to Dara:	  	 Dara Therapeutics, Inc.
 1234 Airport Road, Suite #105

 Destin, FL 32541
 U.S.A.
 Phone: 850-650-1010
 Fax: 850-650-2213

		
	With a copy to:	  	 Jeffrey M. Wiesen, Esq.
 Mintz, Levin, Cohn, Ferris,
Glovsky and
 Popeo, P.C.
 One Financial Center
 Boston, MA 02111
 U.S.A.
 Phone: (617) 542-6000
 Fax: (671) 542-2241

 All notices, requests and other
communications hereunder shall be deemed to have been given either (i) if by hand, at the time of the delivery thereof to the receiving Party at the address of such Party set forth above, (ii) if made by telecopy or facsimile transmission,
at the time that receipt thereof has been acknowledged by electronic confirmation or otherwise, (iii) if sent by private courier, on the third (3rd) business day following the day such notice is delivered to the courier service, or (iv) if sent by registered or certified mail, on the fifth (5th) business day following the day such mailing is made. 
 10.2 Language. This Agreement
has been prepared in the English language and the English language shall control its interpretation. 
 10.3 Governing Law.
This Agreement will be construed, interpreted and applied in accordance with the laws of England (excluding its body of law controlling conflicts of law). 
 10.4 Limitations. Except as set forth elsewhere in this Agreement, neither Party grants to the other Party any right or license to any of its intellectual property. 
  

 19 

 10.5 Entire Agreement. This is the entire Agreement between the Parties with respect to the
subject matter hereof and supersedes all prior representations, understandings and agreements between the Parties with respect to the subject matter hereof including, without limitation, that certain Confidentiality Agreement between the Parties
dated September 26, 2002. No modification shall be effective unless in writing with specific reference to this Agreement and signed by the Parties. 
 10.6 Waiver. The terms or conditions of this Agreement may be waived only by a written instrument executed by the Party waiving compliance. The failure of either Party at any time or times to require
performance of any provision hereof shall in no manner affect its rights at a later time to enforce the same. No waiver by either Party of any condition or term shall be deemed as a continuing waiver of such condition or term or of another condition
or term. 
 10.7 Headings. Section and subsection headings are inserted for convenience of reference only and do not form part
of this Agreement. 
 10.8 Assignment. Neither this Agreement nor any right or obligation hereunder may be assigned, delegated
or otherwise transferred, in whole or part, by either Party without the prior express written consent of the other; provided, however, that either Party may, without the written consent of the other, assign this Agreement and its rights and delegate
its obligations hereunder to its Affiliates, or in connection with the transfer or sale of all or substantially all of such Party’s assets or business related to this Agreement, or in the event of its merger, consolidation, change in control or
similar transaction. Any permitted assignee shall assume all obligations of its assignor under this Agreement. Any purported assignment in violation of this Section 10.8 shall be void. The terms and conditions of this Agreement shall be binding
upon and inure to the benefit of the permitted successors and assigns of the Parties. 
 10.9 Force Majeure. Neither Party
shall be liable for failure of or delay in performing obligations set forth in this Agreement, and neither shall be deemed in breach of its obligations, if such failure or delay is due to natural disasters or any causes beyond the reasonable control
of such Party. In event of such force majeure, the Party affected thereby shall use reasonable efforts to cure or overcome the same and resume performance of its obligations hereunder. 
 10.10 Construction. The Parties hereto acknowledge and agree that: (i) each Party and its counsel reviewed and negotiated the terms
and provisions of this Agreement and have contributed to its revision; (ii) the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation of this Agreement; and
(iii) the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in favor of or against any Party, regardless of which Party was generally responsible for the preparation of this Agreement. 

10.11 Severability. If any provision(s) of this Agreement are or become invalid, are ruled illegal by any court of competent
jurisdiction or are deemed unenforceable under then current applicable law from time to time in effect during the Term hereof, it is the intention of the Parties that the remainder of this Agreement shall not be affected thereby. The Parties hereto
covenant and agree to renegotiate any such term, covenant or application thereof in good faith in 

  

 20 

 
order to provide a reasonably acceptable alternative to the term, covenant or condition of this Agreement or the application thereof that is invalid, illegal
or unenforceable, it being the intent of the Parties that the basic purposes of this Agreement are to be effectuated. 
 10.12
Status. Nothing in this Agreement is intended or shall be deemed to constitute a partner, agency, employer-employee, or joint venture relationship between the Parties. 
 10.13 Further Assurances. Each Party agrees to execute, acknowledge and deliver such further instructions, and to do all such other acts,
as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 10.14 Counterparts. This
Agreement may be executed simultaneously in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives. 
  

									
	DARA THERAPEUTICS, INC.	 		 	KIRIN BREWERY COMPANY, LIMITED
					
	By:	 	 /s/ Steve Gorlin
	 		 	By:	 	 /s/ Katsuhiko Asano

	Name:	 	Steve Gorlin	 		 	Name:	 	Katsuhiko Asano, Ph.D.
	Title:	 	Chairman of the Board of Directors	 		 	Title:	 	Managing Executive Officer
		 		 		 		 	President of Pharmaceutical Division

  

 21 

 Schedule A 
 Licensed Patent Rights 
  

					
	 Patent or Patent Application
	  	 Jurisdiction
	  	 Issue Date or Filing Date

	 US Patent No. 5631238
	  	United States	  	May 20, 1997
			
	 US Patent No. 5461036
	  	United States	  	October 24, 1995

 Schedule B 
 Licensed Technology 
  

	1.	Technology and information developed under the AGREEMENT BETWEEN THE DIVISION OF CANCER TREATMENT DIAGNOSIS AND CENTERS, NATIONAL CANCER INSTITUTE AND KIRIN BREWERY COMPANY LIMITED
FOR THE CLINICAL DEVELOPMENT OF KRN5500, dated January 17, 1996 and amended on November 8, 2002 (the “CTA”). 

  

	2.	Kirin’s Drug Master File 

  

	3.	Kirin’s non-audited reports of clinical trials of KRN5500 in Japan for Dara’s own use 

  

	4.	Kirin’s pre-clinical data on KRN5500, including acute, subchronic and chronic toxicity studies 

  

	5.	Other pre-clinical data of Kirin that Kirin agrees is needed in Dara’s IND 

  

	6.	NCI’s IND 

  

	7.	NCI’s clinical data, including but not limited adverse event and serious adverse event reports, pharmacokinetic and pharmacodynamic data and relevant correspondence with the
FDA

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00142-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00142-of-00352.parquet"}]]